Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
← catalyst calendarNCT05186974 · readout ≤ 42 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
193actual
Sites
101
Countries
Australia, Canada, France +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-30 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Interventions
- Drug: Sacituzumab Govitecan-hziy (SG) — also filed as GS-0132, IMMU-132
- Drug: Pembrolizumab — also filed as KEYTRUDA®
- Drug: Carboplatin — also filed as Paraplatin®
- Drug: Cisplatin — also filed as Platinol®
Primary outcomes
what the primary-completion date above is the date OFObjective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
measured Up to 22 Months
Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts
measured First dose date up to 21 days
Publications
- PMID 41173143 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed